Campos L, Vu Van H, Ville D, Imbert C, Gentilhomme O, Luo Y C, Fiere D, Viala J J
Blut. 1984 Apr;48(4):221-6. doi: 10.1007/BF00319813.
Serum beta 2 microglobulin levels, measured by radioimmunoassay (Phadebas test), were found increased in acute myeloid leukemias at diagnosis. Serum beta 2 microglobulin levels were significantly higher in patients with monocytic leukemias (13 patients, M4-M5 FAB classification) than in those with other cytological types (18 patients). Beta 2 microglobulin levels at diagnosis were correlated with serum lysozyme levels, but they were not correlated with blood blast counts, serum LDH and ferritin levels. 195 serum beta 2 microglobulin measurements were made serially in 30 patients with acute myeloid leukemias in first remission. Compared to values at diagnosis, beta 2 microglobulin levels in remission were significantly decreased. Out of 30 patients in remission 12 had increased serum beta 2 microglobulin levels (greater than 3 mg/l). Serial measurements were not predictive for relapses.
通过放射免疫测定法（法德巴斯试验）测得的血清β2微球蛋白水平在急性髓系白血病诊断时升高。单核细胞白血病患者（13例，FAB分类为M4 - M5）的血清β2微球蛋白水平显著高于其他细胞学类型患者（18例）。诊断时的β2微球蛋白水平与血清溶菌酶水平相关，但与血原始细胞计数、血清乳酸脱氢酶和铁蛋白水平无关。对30例首次缓解期的急性髓系白血病患者进行了195次血清β2微球蛋白连续检测。与诊断时的值相比，缓解期的β2微球蛋白水平显著降低。30例缓解期患者中有12例血清β2微球蛋白水平升高（大于3mg/l）。连续检测对复发无预测作用。
